Prospective observational study to evaluate the efficacy and safety of osimertinib by PK/PD/PGx analysis

Prospective observational study to evaluate the efficacy and safety of osimertinib by PK/PD/PGx analysis - NCCH-1608

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029995

Enrollment

200

Registered

2017-11-16

Start date

2017-06-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 20years or older who are diagnosed lung cancer and scheduled to receive osimertinib.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Response Rate	—

Countries

Japan

Contacts

Public ContactYasushi Goto

National Cancer Center Hospital Thoracic Oncology

ygoto@ncc.go.jp0335422511

Outcome results